A major global evidence update from the United Nations Environment Programme and the World Health Organization says exposure to endocrine-disrupting chemicals can begin before birth and may affect more aspects of human and wildlife health than was understood when the organizations last issued a comprehensive assessment in 2012.
Endocrine-disrupting chemicals, often shortened to EDCs, are substances that can interfere with hormone systems after exposure. The term describes a biological property, not one single family of products. Examples discussed in the wider evidence base include some bisphenols, phthalates, persistent industrial chemicals and certain pesticides.
The new report should not be read as proof that every chemical or every consumer product is dangerous. It is an assessment of a broad and uneven evidence base. Its central message is that the science has strengthened, important gaps remain, and chemical testing and regulation have not kept pace with the number of substances in commerce.
Why early exposure matters
Hormones help regulate growth, brain development, reproduction, metabolism, thyroid function, immunity and cardiovascular processes. These systems can be particularly sensitive during developmental windows such as pregnancy, infancy and puberty.
UNEP and WHO report that EDCs have been detected in blood, breast milk and cord blood. Detection alone does not establish that a specific exposure caused an individual health outcome. It does show that exposure can occur before birth and supports the need to examine timing, dose, mixtures and vulnerability rather than looking only at adult exposure to one substance at a time.
What has changed since 2012
The 2026 assessment is the first major global update in more than a decade. It finds stronger evidence linking EDC exposure with effects on fertility and reproductive development, brain development and neurological function, thyroid and other hormone regulation, metabolism, immunity and cardiovascular health.
The report also identifies newer areas of concern, including metabolic liver disease and possible kidney effects. The authors explicitly note that scientific gaps remain. Associations are not equally strong across all chemicals, outcomes or study designs, and the evidence cannot be reduced to a single universal risk estimate.
A testing gap in a very large chemical market
More than 350,000 chemicals and chemical mixtures are registered for production and use globally, according to the joint release, yet only a small fraction has been evaluated for endocrine-disrupting properties.
That gap matters because existing regulatory systems have often assessed one chemical at a time, while people and wildlife encounter mixtures through food, water, air, dust, workplaces and consumer products. Evaluating mixtures is scientifically difficult, but ignoring them can also underestimate real-world complexity.
Where exposure may occur
Chemicals with endocrine-disrupting properties can be used across plastics, food packaging, toys, medical devices, pesticides, cosmetics, textiles, furnishings and other product chains. A product category is not itself a diagnosis of risk: chemical identity, concentration, migration, route of exposure, frequency and duration all matter.
For consumers, this is an important guardrail against alarm. Broad claims such as “all plastic is toxic” are not supported by the assessment. A more useful approach is to follow specific regulatory advice, use products as directed, avoid heating food in containers not designed for that purpose, and pay attention to credible recalls or safety notices.
What the report asks institutions to do
The companion policy synthesis calls for stronger identification and testing, better monitoring, safer substitution and coordinated action across sectors. It covers food packaging, cosmetics, toys, textiles, health care, agriculture, pharmaceuticals and waste management.
Substitution needs care. Replacing a restricted chemical with a closely related substance that has not been adequately tested can create a “regrettable substitution” in which the apparent solution repeats the same problem. Transparent chemical information and early testing can help regulators and manufacturers compare alternatives more reliably.
What individuals can and cannot control
Personal choices may reduce some exposures, but the report frames EDCs as a systems issue. Consumers cannot evaluate thousands of ingredients or control contamination throughout global supply chains. Product design, disclosure, occupational protections, environmental monitoring and regulation therefore carry much of the responsibility.
Pregnant people or parents do not need to discard every household product. Those with specific concerns can consult official public-health guidance and discuss occupational or unusually high exposures with a clinician. Medical testing for EDC exposure is not a routine screening tool for most people and should not be purchased or interpreted without qualified advice.
The responsible takeaway
The 2026 update strengthens the case for prevention and better chemical governance, especially during sensitive developmental periods. It does not provide a simple list that divides every product into “safe” and “unsafe,” nor does it prove that a particular chemical caused a particular person’s illness.
The evidence is most useful when it improves testing, transparency and safer product design while keeping communication precise. That combination can protect health without turning a complex environmental-health issue into fear or unsupported consumer advice.
Sources: UNEP–WHO joint news release and the State of the Science on Endocrine-Disrupting Chemicals 2026.
This article is for general information and does not replace medical or occupational-health advice.













